Harmen Beurmanjer

141 Publications and grants Publications and grants Peer reviewed publications: Wolf C. J. H., Beurmanjer H., Dijkstra B. A.G., Geerlings A., Spoelder M., Homberg J. R., Schellekens A. F.A. (2021) Characterization of the GHB withdrawal syndrome. Journal of Clinical Medicine. Dijkstra B. A. G., Beurmanjer H., Goudriaan A. E., Schellekens A. F. A., Joosten E. A. G. (2021) Unity in diversity: A systematic review on the GHB using population. International Journal of Drug Policy . Bruijnen, C. J. W. H., Dijkstra, B. A. G., Walvoort, S. J. W., Budy, M. J. J., Beurmanjer, H., De Jong, C. A. J., & Kessels, R. P. C. (2020). Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18–70. International Journal of Psychiatry in Clinical Practice Beurmanjer, H., Luykx, J. J., De Wilde, B., van Rompaey, K., Buwalda, V. J. A., De Jong, C. A. J., Dijkstra, B. A. G., Schellekens, A. F. A. (2020). Tapering with Pharmaceutical GHB or Benzodi- azepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands. CNS Drugs Beurmanjer, H., Asperslag, E. M., Oliemeulen, L., Goudriaan, A. E., De Jong, C. A. J., Schellekens, A. S. A., & Dijkstra, B. A. G. (2019). A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder. European Addiction Research . Beurmanjer, H., Kamal, R. M., de Jong, C. A. J., Dijkstra, B. A. G., & Schellekens, A. F. A. (2018). Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. CNS Drugs Van Montfoort-De Rave K. F.G., De Weert-Van Oene G. H., Beurmanjer H., Koekkoek B. (2017) Late-onset alcohol dependence: patient-reported problems. Addiction Research and Theory . 25(2):139–45. Kamal R.M., van Noorden M.S., Wannet W., Beurmanjer H., Dijkstra B. A. G., Schellekens A. F. A. (2017) Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. CNS Drugs . 31(1):51–64.